Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399040 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
US9278101 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
US8173707 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
US8586633 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
US8173707 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
US8586633 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
US9278101 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
US9399040 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
US9066856 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(9 years from now) | |
US9486406 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 30, 2017 |
New Patient Population(NPP) | Dec 08, 2020 |
Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: Maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain
Dosage: SOLUTION;IRRIGATION